Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-α, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis

Jung Wook Kim, Hyo Jong Kim, Chang Kyun Lee, Jae Jun Shim, Jae Young Jang, Suk Ho Dong, Byung Ho Kim, Young Woon Chang, Sung-Gil Chi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Protein kinase C delta binding protein (PRKCDBP/Cavin3/hSRBC) is a putative tumor suppressor that is downregulated in many human cancers. Recently, PRKCDBP was identified to be activated by nuclear factor-κB in response to tumor necrosis factor (TNF)-α.

Aims: To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-α signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy.

Methods: In total, 31 IFX therapy-naïve patients (13 females; median age, 41 years) with moderate-to-severe UC who had been scheduled for IFX treatment were included. Immunohistochemical analysis of TNF-α and PRKCDBP expression was performed in rectal biopsies.

Results: A significant correlation was observed in immunoreactivity between TNF-α and PRKCDBP. IFX therapy reduced immunohistochemical expression of PRKCDBP and TNF-α (P < 0.001 and P = 0.005, respectively). The mean PRKCDBP expression level decreased from 54.5 to 30.2 %, and that of TNF-α decreased from 54.5 to 36.2 %. The immunohistochemical expression pre- and post-PRKCDBP therapy correlated significantly with TNF-α levels pre- and post-therapy (Spearman’s rank correlation test; P = 0.005 and P = 0.001, respectively).

Conclusions: These results demonstrate that mucosal expression of PRKCDBP correlated strongly with TNF-α expression in UC patients and that IFX therapy resulted in profound reductions in both PRKCDBP and TNF-α. Thus, these findings support that PRKCDBP expression is tightly controlled by TNF-α, and the anti-inflammatory effect of IFX may in part stem from blockade of the TNF-α-PRKCDBP signaling pathway.

Original languageEnglish
Pages (from-to)2947-2957
Number of pages11
JournalDigestive Diseases and Sciences
Volume59
Issue number12
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Ulcerative Colitis
Down-Regulation
Tumor Necrosis Factor-alpha
Therapeutics
Infliximab
Protein Kinase C-delta
Inflammatory Bowel Diseases
Neoplasms
Carrier Proteins
Anti-Inflammatory Agents
Biopsy

Keywords

  • Immunohistochemistry
  • Infliximab
  • PRKCDBP
  • Tumor necrosis factor-alpha
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Physiology

Cite this

Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-α, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis. / Kim, Jung Wook; Kim, Hyo Jong; Lee, Chang Kyun; Shim, Jae Jun; Jang, Jae Young; Dong, Suk Ho; Kim, Byung Ho; Chang, Young Woon; Chi, Sung-Gil.

In: Digestive Diseases and Sciences, Vol. 59, No. 12, 01.01.2014, p. 2947-2957.

Research output: Contribution to journalArticle

Kim, Jung Wook ; Kim, Hyo Jong ; Lee, Chang Kyun ; Shim, Jae Jun ; Jang, Jae Young ; Dong, Suk Ho ; Kim, Byung Ho ; Chang, Young Woon ; Chi, Sung-Gil. / Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-α, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis. In: Digestive Diseases and Sciences. 2014 ; Vol. 59, No. 12. pp. 2947-2957.
@article{cd16f57253744d5981a77286aded3460,
title = "Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-α, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis",
abstract = "Background: Protein kinase C delta binding protein (PRKCDBP/Cavin3/hSRBC) is a putative tumor suppressor that is downregulated in many human cancers. Recently, PRKCDBP was identified to be activated by nuclear factor-κB in response to tumor necrosis factor (TNF)-α.Aims: To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-α signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy.Methods: In total, 31 IFX therapy-na{\"i}ve patients (13 females; median age, 41 years) with moderate-to-severe UC who had been scheduled for IFX treatment were included. Immunohistochemical analysis of TNF-α and PRKCDBP expression was performed in rectal biopsies.Results: A significant correlation was observed in immunoreactivity between TNF-α and PRKCDBP. IFX therapy reduced immunohistochemical expression of PRKCDBP and TNF-α (P < 0.001 and P = 0.005, respectively). The mean PRKCDBP expression level decreased from 54.5 to 30.2 {\%}, and that of TNF-α decreased from 54.5 to 36.2 {\%}. The immunohistochemical expression pre- and post-PRKCDBP therapy correlated significantly with TNF-α levels pre- and post-therapy (Spearman’s rank correlation test; P = 0.005 and P = 0.001, respectively).Conclusions: These results demonstrate that mucosal expression of PRKCDBP correlated strongly with TNF-α expression in UC patients and that IFX therapy resulted in profound reductions in both PRKCDBP and TNF-α. Thus, these findings support that PRKCDBP expression is tightly controlled by TNF-α, and the anti-inflammatory effect of IFX may in part stem from blockade of the TNF-α-PRKCDBP signaling pathway.",
keywords = "Immunohistochemistry, Infliximab, PRKCDBP, Tumor necrosis factor-alpha, Ulcerative colitis",
author = "Kim, {Jung Wook} and Kim, {Hyo Jong} and Lee, {Chang Kyun} and Shim, {Jae Jun} and Jang, {Jae Young} and Dong, {Suk Ho} and Kim, {Byung Ho} and Chang, {Young Woon} and Sung-Gil Chi",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10620-014-3282-4",
language = "English",
volume = "59",
pages = "2947--2957",
journal = "American Journal of Digestive Diseases",
issn = "0002-9211",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-α, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis

AU - Kim, Jung Wook

AU - Kim, Hyo Jong

AU - Lee, Chang Kyun

AU - Shim, Jae Jun

AU - Jang, Jae Young

AU - Dong, Suk Ho

AU - Kim, Byung Ho

AU - Chang, Young Woon

AU - Chi, Sung-Gil

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Protein kinase C delta binding protein (PRKCDBP/Cavin3/hSRBC) is a putative tumor suppressor that is downregulated in many human cancers. Recently, PRKCDBP was identified to be activated by nuclear factor-κB in response to tumor necrosis factor (TNF)-α.Aims: To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-α signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy.Methods: In total, 31 IFX therapy-naïve patients (13 females; median age, 41 years) with moderate-to-severe UC who had been scheduled for IFX treatment were included. Immunohistochemical analysis of TNF-α and PRKCDBP expression was performed in rectal biopsies.Results: A significant correlation was observed in immunoreactivity between TNF-α and PRKCDBP. IFX therapy reduced immunohistochemical expression of PRKCDBP and TNF-α (P < 0.001 and P = 0.005, respectively). The mean PRKCDBP expression level decreased from 54.5 to 30.2 %, and that of TNF-α decreased from 54.5 to 36.2 %. The immunohistochemical expression pre- and post-PRKCDBP therapy correlated significantly with TNF-α levels pre- and post-therapy (Spearman’s rank correlation test; P = 0.005 and P = 0.001, respectively).Conclusions: These results demonstrate that mucosal expression of PRKCDBP correlated strongly with TNF-α expression in UC patients and that IFX therapy resulted in profound reductions in both PRKCDBP and TNF-α. Thus, these findings support that PRKCDBP expression is tightly controlled by TNF-α, and the anti-inflammatory effect of IFX may in part stem from blockade of the TNF-α-PRKCDBP signaling pathway.

AB - Background: Protein kinase C delta binding protein (PRKCDBP/Cavin3/hSRBC) is a putative tumor suppressor that is downregulated in many human cancers. Recently, PRKCDBP was identified to be activated by nuclear factor-κB in response to tumor necrosis factor (TNF)-α.Aims: To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-α signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy.Methods: In total, 31 IFX therapy-naïve patients (13 females; median age, 41 years) with moderate-to-severe UC who had been scheduled for IFX treatment were included. Immunohistochemical analysis of TNF-α and PRKCDBP expression was performed in rectal biopsies.Results: A significant correlation was observed in immunoreactivity between TNF-α and PRKCDBP. IFX therapy reduced immunohistochemical expression of PRKCDBP and TNF-α (P < 0.001 and P = 0.005, respectively). The mean PRKCDBP expression level decreased from 54.5 to 30.2 %, and that of TNF-α decreased from 54.5 to 36.2 %. The immunohistochemical expression pre- and post-PRKCDBP therapy correlated significantly with TNF-α levels pre- and post-therapy (Spearman’s rank correlation test; P = 0.005 and P = 0.001, respectively).Conclusions: These results demonstrate that mucosal expression of PRKCDBP correlated strongly with TNF-α expression in UC patients and that IFX therapy resulted in profound reductions in both PRKCDBP and TNF-α. Thus, these findings support that PRKCDBP expression is tightly controlled by TNF-α, and the anti-inflammatory effect of IFX may in part stem from blockade of the TNF-α-PRKCDBP signaling pathway.

KW - Immunohistochemistry

KW - Infliximab

KW - PRKCDBP

KW - Tumor necrosis factor-alpha

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84912523063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912523063&partnerID=8YFLogxK

U2 - 10.1007/s10620-014-3282-4

DO - 10.1007/s10620-014-3282-4

M3 - Article

C2 - 25052149

AN - SCOPUS:84912523063

VL - 59

SP - 2947

EP - 2957

JO - American Journal of Digestive Diseases

JF - American Journal of Digestive Diseases

SN - 0002-9211

IS - 12

ER -